Patents Assigned to Henry M. Jackson Foundation
-
Patent number: 12070462Abstract: Chemical compounds for the treatment of myeloid neoplasms and solid tumors are described, where the compounds were identified through a screening process assessing the binding affinity of the compounds to a synthesized fragment of Setbp1 protein.Type: GrantFiled: May 22, 2019Date of Patent: August 27, 2024Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Yang Du, Nhu Nguyen
-
Patent number: 12042533Abstract: Compositions useful as poliovirus immunogens are provided along with methods and compositions for preparing the same. Compositions comprising poliovirus immunogens can enable a host response that includes virus-neutralizing antibodies which can protect the host from infection and/or disease.Type: GrantFiled: March 29, 2019Date of Patent: July 23, 2024Assignees: BIOLOGICAL MIMETICS, INC., THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INCInventors: Gregory J. Tobin, Michael J. Daly
-
Publication number: 20240174735Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.Type: ApplicationFiled: February 13, 2024Publication date: May 30, 2024Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
-
Patent number: 11967410Abstract: Methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. Also, algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.Type: GrantFiled: February 22, 2018Date of Patent: April 23, 2024Assignees: Meso Scale Technologies, LLC, THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: William F Blakely, Eli N. Glezer, John Kenten, Sudeep Kumar, Anu Mathew, Natalia I. Ossetrova, George Sigal
-
Patent number: 11963959Abstract: Inhibitors against SARS-COV-1, SARS-CoV-2 (Covid-19), MERS-CoV, and variants within each, including methods of treating a subject suffering from such respiratory disease.Type: GrantFiled: August 12, 2022Date of Patent: April 23, 2024Assignees: Southwest Research Institute, The Government of the United States, as represented by The Secretary of the Army, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Jonathan A. Bohmann, Nadean M. Gutierrez, Joseph A. Mcdonough, Robert Francis Campbell, Michael Gordon Joyce, Rekha Panchal, Rajeshwer Sankhala, Allen Duplantier
-
Patent number: 11926656Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.Type: GrantFiled: December 16, 2021Date of Patent: March 12, 2024Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Wei Bu, Masaru Kanekiyo, Michael Gordon Joyce, Jeffrey I. Cohen
-
Patent number: 11913076Abstract: The present disclosure provides gene expression profiles that are associated with prostate cancer, including certain gene expression profiles that differentiate between subjects of African and Caucasian descent and other gene expression profiles that are common to subjects of both African and Caucasian descent. The gene expression profiles can be measured at the nucleic acid or protein level and used to stratify prostate cancer based on ethnicity. The gene expression profiles can also be used to identify a subject for prostate cancer treatment. Also provided are kits for diagnosing and prognosing prostate cancer and an array comprising probes for detecting the unique gene expression profiles associated with prostate cancer in subjects of African and/or Caucasian descent.Type: GrantFiled: May 8, 2018Date of Patent: February 27, 2024Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: Shiv K. Srivastava, Gyorgy Petrovics, Indu Kohaar
-
Patent number: 11884718Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.Type: GrantFiled: April 24, 2019Date of Patent: January 30, 2024Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israeli Deaconess Medical Center, Inc., The Government Of The United States As Represented By The Secretary Of The ArmyInventors: Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce, Rajeshwer Singh Sankhala, Kathryn Elaine Stephenson
-
Patent number: 11865111Abstract: Antiviral drugs targeting the N-terminal domain (NTD) of the spike receptor binding domain (RBD) and methods of treating a subject suffering from coronavirus.Type: GrantFiled: August 11, 2022Date of Patent: January 9, 2024Assignees: Southwest Research Institute, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the United States, as Represented by the Secretary of the ArmyInventors: Jonathan A. Bohmann, Nadean M. Gutierrez, Joseph A. McDonough, Robert Francis Campbell, Michael Gordon Joyce, Rekha Panchal, Rajeshwer Sankhala, Allen Duplantier
-
Publication number: 20230355126Abstract: Multidimensional MRI-based methods permit identification and categorization of brain specimens to identify sub-voxel tissue components that are specific to traumatic axon injury or other lesions. Lower dimensional MR spectral data is acquired and processed to provide multidimensional MR data of higher dimensions. One or more spectral ranges are selected that define signatures for brain injury and evaluation of the multidimensional MR data in these ranges is used to locate voxels associated with brain injury. For example, partial one dimensional data sets such as T1, T2, and mean diffusion coefficient (MD) data sets can be combined to provide two dimensional data sets such as T1-T2, MD-T2, and MD-T1 data sets. Using the spectral signatures, a specimen image can be produced showing areas of lesser or greater injury.Type: ApplicationFiled: July 14, 2021Publication date: November 9, 2023Applicants: The Henry M. Jackson Foundation for the Advancement for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: Dan Haim Benjamini, Peter J. Basser, Diego Iacono
-
Patent number: 11800983Abstract: Featured are methods, apparatus and devices for detecting a hematoma in tissue of a patient. In one aspect, such a method includes emitting near infrared light continuously into the tissue from a non-stationary near infrared light emitter and continuously monitoring the tissue using a non-stationary probe so as to continuously detect reflected light. The near infrared light is emitted at two distances from a brain of the patient, so the emitted light penetrates to two different depths. Such a method also includes applying a ratiometric analysis to the reflected light to distinguish a border between normal tissue and tissue exhibiting blood accumulation.Type: GrantFiled: August 30, 2017Date of Patent: October 31, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Jason D. Riley, Franck Amyot, Amir H. Gandjbakhche, James G. Smirniotopoulos, Eric Wassermann
-
Publication number: 20230285539Abstract: The present disclosure relates to the field of vaccines and binding molecules, as well as preparations and methods of their use in the treatment and/or prevention of disease. Described are vaccines and binding molecules, compositions containing the same, and uses thereof for treating or preventing coronavirus infections, in particular, ?-coronaviruses such as SARS- CoV-2, the causative agent of COVID-19, as well as SARS-CoV-1 and other coronaviruses.Type: ApplicationFiled: March 8, 2021Publication date: September 14, 2023Applicants: Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the United States, as Represented by the Secretary of the ArmyInventors: Michael Gordon JOYCE, Kayvon MODJARRAD
-
Publication number: 20230280349Abstract: In aspects, the disclosure provides a method of differentiating a malignant tumor from a non-malignant tumor in a mammal having a tumor comprising determining in a sample from the mammal the level of one or more of: (1) transthyretin (TTR) RNA or protein, (2) dual oxidase 2 (DUOX2) RNA or protein, and (3) G-protein coupled receptor 179 (GPR179) RNA or protein.Type: ApplicationFiled: March 1, 2023Publication date: September 7, 2023Applicants: The University of Chicago, Inova Health System, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Ayman Al-Hendy, Hiba Alkelani, Thomas Patrick Conrads, George Larry Maxwell, Nicholas William Bateman, Waleed Barakat
-
Patent number: 11744829Abstract: Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A receptor antagonist (such as an antimuscarinic compound, such as caramiphen), as well as methods of treating, reducing the risks of, or preventing a neurological condition such as epilepsy, seizures, post-traumatic stress disorder, status epilepticus, depression, or anxiety, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMDA receptor antagonist (such as an antimuscarinic compound, such as caramiphen). The methods may further comprise administering a positive allosteric modulator of synaptic GABAA receptors, such as a benzodiazepine, such as midazolam, to the subject. The methods are suitable for use in children and adults. Related compositions and uses also are described.Type: GrantFiled: June 28, 2021Date of Patent: September 5, 2023Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Maria F. Braga, Vassiliki Aroniadou-Anderjaska
-
Publication number: 20230266418Abstract: Diffusion sensitizing gradient pulse pairs are prescribed in a manner to mitigate effects of concomitant gradient artifacts. Measured MR signals generated by applying a plurality of diffusion sensitizing gradient matrices are obtained and processed to determine a second order mean diffusion tensor and a fourth order covariance tensor. Quantities derived from these tensors are measured and mapped within an imaging volume which describe features of diffusion anisotropy and heterogeneity within each imaging voxel.Type: ApplicationFiled: July 8, 2021Publication date: August 24, 2023Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Magdoom Mohamed Kulam Najmudeen, Peter J. Basser, Michal E. Komlosh
-
Publication number: 20230241196Abstract: Methods are disclosed for inducing an immune response to Neisseria gonorrhoeae in a mammalian subject. These methods include administering to the mammalian subject an effective amount of a MetQ protein and an effective amount of a K-type CpG oligodeoxynucleotide, thereby inducing the immune response. Also disclosed are immunogenic compositions including an effective amount of a MetQ protein and an effective amount of a K-type CpG oligodeoxynucleotide.Type: ApplicationFiled: January 26, 2021Publication date: August 3, 2023Applicants: Oregon State University, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Aleksandra E. Sikora, Ryszard A. Zielke, Ann E. Jerse
-
Patent number: 11648239Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.Type: GrantFiled: January 26, 2021Date of Patent: May 16, 2023Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Albert L. Dobi, Clifton L. Dalgard, Shiv K. Srivastava
-
Patent number: 11600373Abstract: The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.Type: GrantFiled: August 29, 2019Date of Patent: March 7, 2023Assignees: MESO SCALE TECHNOLOGIES, LLC., THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: William F. Blakely, Eli N. Glezer, John Kenten, Sudeep Kumar, Anu Mathew, Natalia I. Ossetrova, George Sigal
-
Patent number: 11583578Abstract: The invention relates to pharmaceutical compositions comprising at least one antigen and an adjuvant composition, where the adjuvant composition comprises a saponin and a liposome. The liposome of the composition comprises monophosphoryl lipid A (MPLA), cholesterol and a phospholipid that is in a liquid crystalline state at greater than or equal to 23° C., and the concentration of cholesterol to lipid in the liposome is greater than 50% (mol/mol). The antigen in the composition is a soluble Plasmodium falciparum recombinant circumsporozoite protein (rCSP) comprising the amino acid sequence of SEQ ID NO:1, or a P. falciparum rCSP peptide that is at least 95% identical to the amino acid sequence of SEQ ID NO:1.Type: GrantFiled: April 27, 2018Date of Patent: February 21, 2023Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government Of The United States, As Represented By The Secretary Of The ArmyInventors: Sheetij Dutta, Zoltan Beck, Carl Alving, Gary Matyas
-
Patent number: 11572389Abstract: Provided are antigenic compositions and uses thereof that include at least two human herpesvirus (HHV) polypeptides involved in mediating HHV binding, fusion, and entry into host cells, such as gp350, gH, gL, and gB, or nucleic acids encoding the polypeptides. The two HHV polypeptides comprise any combination of: a gB polypeptide; a gp350 polypeptide; a gL polypeptide; and a gH polypeptide, and optionally any one or more of the following polypeptides: gp42, gM, gN, gl, gC, gE, gD, ORF68, BMRF-2, BDLF2, UL128, UL130, UL131A, and gpK8.1. Also disclosed are methods of inducing an immune response or treating or preventing an HHV infection in a subject by administering to the subject at least two of the HHV polypeptides or nucleic acid(s) encoding the same. Methods of passively transferring immunity using high-titer anti-HHV antibodies or immune cells are also disclosed.Type: GrantFiled: January 26, 2018Date of Patent: February 7, 2023Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: Xinle Cui, Clifford M. Snapper